AVI-009 / Avicenna Biosciences - LARVOL DELTA

Avicenna Biosciences Secures U.S. Patent for Novel Compounds That Can Be Used in the Treatment of Neurodegenerative Diseases (Businesswire) - "Avicenna Biosciences...today announced it has secured its first composition of matter patent. Entitled 'Azaindole ROCK Inhibitors,' U.S. Patent (12,116,366) (the ‘366 patent) grants Avicenna exclusive rights to compounds that inhibit Rho associated protein kinases 1 and 2 (ROCK1/2), pharmaceutical compositions that contain the compounds, and methods of treating neurodegenerative diseases with the compounds, including ALS and Parkinson’s disease...With a recent animal study showing that AVI-009 is potent, highly selective and well-tolerated, Avicenna is initiating the studies required to begin human trials and will prepare to launch a Phase 1 clinical trial of AVI-009 later next year."

New P1 trial • Patent • Amyotrophic Lateral Sclerosis • CNS Disorders • Parkinson's Disease